Review of 2017: two hot and cold days in the pharmaceutical industry

[China Pharmaceutical network industry trends] from January to September of this year, China's GDP was 59.3 trillion yuan, a year-on-year growth of 6.9%, showing a steady and positive trend, while the growth rate of the added value of the pharmaceutical industry was 11.6%, higher than the GDP of p4.7%, significantly higher than the growth rate of all industries and DGP Recently, the China Pharmaceutical Industry Information Center issued the 2017 China pharmaceutical industry economic operation index, which pointed out that the main business income of China's pharmaceutical industry is expected to exceed 3.3 trillion yuan, and the growth rate will reach 12.2% Driven by the policy, the pharmaceutical industry has become the engine of China's sustainable economic development The operation index pointed out that the growth rate of total profit index of China's pharmaceutical industry was slightly higher than that of the main business income index, and the growth rate of total profit index showed a steady and rising trend in recent two years From the perspective of profitability index, pharmaceutical industry enterprises have been maintaining a relatively high profitability, which fully shows that the pharmaceutical manufacturing industry has the characteristics of long-term anti economic fluctuations Wu Haidong, deputy director general of the Department of consumer goods industry of the Ministry of industry and information technology, pointed out that from January to September this year, China's gross domestic product (GDP) was 59.3 trillion yuan, up 6.9% year-on-year, showing a steady and positive trend, while the growth rate of the added value of the pharmaceutical industry was 11.6%, higher than that of GDP by p4.7 percentage points, significantly higher than that of all industries and DGP Encourage innovation According to the operation index, the sub industries of the pharmaceutical industry are mainly from the perspective of main revenue and total profit The processing of Chinese herbal pieces, health materials and medical supplies, biological drugs and medical devices are all in the top 4 of the industry, higher than the average level of the pharmaceutical industry Under the background that the State encourages the improvement of drug quality and the development of innovative drugs, the pharmaceutical enterprises focusing on R & D and innovation ushered in good results In December 2016, the State Council issued the notice on printing and distributing the national strategic emerging industry development plan for the 13th five year plan, which clearly stated that we should accelerate the development of innovative drugs and biological products with major clinical needs, promote the international development of the industry, and build a biomedical power With the standardization of generic drugs and the policy guidance of innovative drugs, pharmaceutical companies are increasing their research and development in the field of new drugs According to the CPM database of China Pharmaceutical Industry Information Center, from 2012 to 2017, Hengrui pharmaceutical applied for a total of 17 class 1 chemicals, which is undoubtedly the pioneer of innovative drug research and development, while Zhengda Tianqing and Guangdong Dongguang have 14 each, which are in the echelon of new drug research and development Shanghai Pharmaceutical Research Institute, Jiangsu Haosen and Zhejiang Haizheng followed with 9, 7 and 6 new drug applications respectively, and Jiangsu Kangyuan, Yangtze River, Shenyang Sansheng and Yabao pharmaceutical also actively participated in new drug applications Up to now, domestic pharmaceutical companies have gradually transformed and upgraded from generic drugs to R & D innovation In the future, new drug research and development will play an increasingly important role in the development of Chinese pharmaceutical enterprises   In October 2017, the general office of the CPC Central Committee, together with the general office of the State Council, issued the opinions on deepening the reform of the review and approval system and encouraging the innovation of pharmaceutical and medical devices, encouraging the research and development of new drugs and innovative medical devices, supporting the major national science and technology projects and the national key research and development plans, and the new drugs that were carried out by the national clinical medical research center and approved by the central management department Priority shall be given to the review and approval of drugs and innovative medical devices On December 17, China Pharmaceutical Industry Information Center released "2017 China innovative pharmaceutical enterprises", "2017 China innovative medical device enterprises", which were all shortlisted by famous pharmaceutical enterprises such as Zhengda Tianqing, Jiangsu Haosen, Yangzi River, Sinopharm holding, Tongrentang, etc For a long time, China's pharmaceutical industry has been dominated by generic drugs, lacking innovative drugs with independent intellectual property rights The industry generally believes that the research and development of new drugs is a comprehensive and systematic project, which requires the guidance and support of the state in policy, the design and completion of high-level clinical trials by high-level clinical experts, and the continuous investment of pharmaceutical enterprises Several key factors are indispensable With the rapid development of the pharmaceutical industry, the revenue growth of Chinese patent medicine has slowed down slightly According to the data of the National Bureau of statistics, from January to September this year, the overall growth rate of revenue of traditional Chinese medicine sector from January to September 2017 was 10.19%, lower than the average growth level of the pharmaceutical industry In the past two years, due to the large amount of medical insurance resources occupied by Chinese patent medicine (especially traditional Chinese medicine injection), some provinces and cities have restricted its clinical use In February 2017, the Ministry of human resources and social security released the new catalogue of drugs for national basic medical insurance, industrial injury insurance and maternity insurance, which limits the indications for the use of many Chinese patent medicines and directly leads to the sales scope of these medicines According to the requirements of the Ministry of human resources and social security of the people's Republic of China, the intelligent monitoring system for medical services of basic medical insurance and the monitoring and analysis system for the use of drugs for social insurance shall be established and improved, focusing on the monitoring of drugs with large consumption, high expenditure and possible unreasonable use, and the monitoring results shall be released to the society in an appropriate way In addition, there are many kinds of traditional Chinese medicine injections, under strict control, the market growth rate is even weaker According to the statistics, in 2016, when the annual growth rate of China's pharmaceutical industry reached 10.3%, the market growth rate of traditional Chinese medicine injection industry was less than 1% In November 2017, Sichuan public hospitals were "held accountable" by Sichuan health and family planning commission due to poor drug use control, and all public hospitals in the province were required to meet the standards, or the president was dismissed, and all employees were fined Since then, various provinces and cities have introduced public hospital fee control programs According to incomplete statistics of jianzhijun, up to now, 15 provinces, including Hebei, Shanxi, Inner Mongolia, Liaoning, Jiangsu, Anhui, Hubei, Yunnan, Fujian, Sichuan, Guangxi, Qinghai, Gansu and Guangdong, have issued relevant policies to clearly indicate the plan of key supervision or restricted use of auxiliary drugs In the cost control war, Chinese patent medicine has focused on monitoring the target, and it is inevitable that the market of Chinese patent medicine will be affected in the future Analysts pointed out that those varieties of Chinese patent medicines with clinical efficacy must be evaluated after being put on the market to survive Original title: double hot and cold days in the pharmaceutical industry in 2017: Biopharmaceutics ushered in the spring, and the growth rate of Chinese patent medicine slowed down